Remynd

Info

reMYND drives the development of disease-modifying treatments against protein misfolding disorders

Geschiedenis

reMYND drives the development of disease-modifying treatments against protein misfolding disorders

reMYND NV, founded in 2002 as a spin-off from the University of Leuven, drives the development of disease-modifying treatments against Alzheimer’s, Parkinson’s, Diabetes and other orphan protein misfolding disorders. reMYND is organized along two independently managed business units, the Contract Research Organization (CRO) and the own Drug Discovery & Development unit:

Contract Research
The in-vivo Contract Research Organization (CRO) helps its clients assess the pharmacokinetics and -dynamics of their experimental treatments against Alzheimer's disease in reMYND’s proprietary Alzheimer mouse models. Its mission is to be a strategic partner for its clients and help them identify the most promising set-up to assess potential effects.

Given the extensive experience fully focused on Alzheimer's, reMYND’s CRO can contribute its expertise for every type of Alzheimer treatment in any form of application.

The CRO is serving 6 of the Top 10 pharmaco’s worldwide and its client-base covers the US, Europe and Japan. The CRO has provided in-vivo proof-of-concept data for several candidate drugs that reMYND’s clients have currently in clinical development.

Drug discovery
reMYND’s own Drug Discovery & Development unit focuses entirely on disease-modifying treatments with the aim to decelerate – or even reverse – cellular degeneration found in protein misfolding disorders, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), type 2 diabetes mellitus (T2DM) and several orphan diseases.

As such, reMYND responds to a clear unmet medical need, as all marketed treatments and the majority of the products under development world-wide are aimed mainly to mitigate symptoms.
reMYND’s pipeline primarily consists of 4 disease-modifying programs counteracting tau-toxicity for AD, 2 programs for T2DM, and 2 counteracting synuclein-toxicity for PD, with recent additions in orphan diseases.

In addition, reMYND grants licenses and markets commercial kits of RadarScreen, a technology for rapid and cost-effective identification of genotoxic liabilities in early stage drug discovery.

reMYND has been substantially supported by grants from IWT and from The Michael J Fox Foundation.

"reMYND is a clinical stage company developing treatments for Alzheimer’s, diabetes and other diseases caused by cellular dysfunction. It is backed by a proprietary drug discovery platform, which enables the identification of novel mechanisms-of-action, targets and first-in-class small molecules.reMYND’s most advanced program is ReS19-T, an investigational compound for the treatment of Alzheimer’s, which entered the clinic in Q4 2020. In animal models it has been shown to produce an acute response, restoring synaptic plasticity, a process central in the disease cascade leading to neuronal demise and build-up of plaques and tangles."